Technical Analysis for VRML - Vermillion, Inc.

Grade Last Price % Change Price Change
grade A 1.36 0.74% 0.01
VRML closed up 0.74 percent on Friday, March 22, 2019, on 1.81 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Mar 28

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical VRML trend table...

Date Alert Name Type % Chg
Mar 22 Wide Bands Range Expansion 0.00%
Mar 22 Overbought Stochastic Strength 0.00%
Mar 21 Wide Bands Range Expansion 0.74%
Mar 21 Overbought Stochastic Strength 0.74%
Mar 20 Wide Bands Range Expansion 0.74%
Mar 20 Overbought Stochastic Strength 0.74%
Mar 19 Calm After Storm Range Contraction 3.03%
Mar 19 Inside Day Range Contraction 3.03%
Mar 19 Wide Bands Range Expansion 3.03%
Mar 19 Overbought Stochastic Strength 3.03%

Older signals for VRML ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Vermillion, Inc., together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic tests that help physicians diagnose, treat, and enhance outcomes for patients. The company develops diagnostic tests in the fields of oncology, cardiology, and women's health. Its lead product is OVA1, an ovarian cancer blood test for pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. The company is also involved in developing various programs in other clinical aspects of ovarian cancer, as well as in peripheral arterial disease. Vermillion, Inc. has strategic alliance agreement with Quest Diagnostics Incorporated to develop and commercialize diagnostic tests. It serves clinical reference laboratories, hospital laboratories, and physician offices. The company was formerly known as Ciphergen Biosystems, Inc. and changed its name to Vermillion, Inc. in August 2007. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.
Medicine Health Medical Specialties Oncology New Jersey Ovarian Cancer Diagnostic Tests Corning Inc. Peripheral Arterial Disease Gynaecological Cancer Quest Diagnostics
Is VRML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 1.45
52 Week Low 0.1
Average Volume 183,907
200-Day Moving Average 0.6701
50-Day Moving Average 0.8489
20-Day Moving Average 1.0355
10-Day Moving Average 1.285
Average True Range 0.1114
ADX 51.52
+DI 28.6182
-DI 5.6222
Chandelier Exit (Long, 3 ATRs ) 1.0658
Chandelier Exit (Short, 3 ATRs ) 1.0241999999999999
Upper Bollinger Band 1.5588
Lower Bollinger Band 0.5122
Percent B (%b) 0.81
BandWidth 101.071946
MACD Line 0.1677
MACD Signal Line 0.1391
MACD Histogram 0.0285
Fundamentals Value
Market Cap 76.38 Million
Num Shares 56.2 Million
EPS -0.22
Price-to-Earnings (P/E) Ratio -6.18
Price-to-Sales 25.03
Price-to-Book 16.79
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.54
Resistance 3 (R3) 1.53 1.46 1.51
Resistance 2 (R2) 1.46 1.41 1.46 1.50
Resistance 1 (R1) 1.41 1.38 1.42 1.42 1.49
Pivot Point 1.34 1.34 1.34 1.34 1.34
Support 1 (S1) 1.29 1.29 1.30 1.30 1.23
Support 2 (S2) 1.22 1.26 1.22 1.22
Support 3 (S3) 1.17 1.22 1.21
Support 4 (S4) 1.18